In a world obsessed with flashy AI drug discovery, PharmaCytics is playing a different game entirely. They're not chasing algorithms; they're engineering molecules. With just 6 employees and $1.2M in revenue, they're betting everything on a niche that could redefine how we deliver medicine.

"They're not building a platform for everyone—they're building a precision tool for a specific problem."

Their tech stack reveals a modern but pragmatic approach. Tailwind CSS, Bootstrap, and jQuery suggest they're building a functional but not overly complex digital presence. The use of Swiper and Lazy Loading indicates attention to user experience, even if the audience is small. This isn't a company burning cash on flashy web development—they're spending it on molecules.

• Prodrug specialization is a high-barrier moat—few competitors can match their focus
• Zero marketing spend suggests confidence in their science over their sales funnel
• The 6-person team implies either pre-funding or post-acquisition readiness
• Gerrit Veeneman's presence signals deep scientific credibility